The effect of the European Clinical Trials Directive on published drug research in anaesthesia

The clinical indications for anaesthetic drugs are developed through peer-reviewed publication of clinical trials. We performed a bibliometric analysis of all human research papers reported in nine general anaesthesia journals over 6 years (n = 6489), to determine any effects of the 2004 European Cl...

Full description

Bibliographic Details
Main Authors: Walker, E (Author), Hankins, M.C (Author), White, S.M (Author)
Format: Article
Language:English
Published: 2009-09.
Subjects:
Online Access:Get fulltext
LEADER 01641 am a22001453u 4500
001 187315
042 |a dc 
100 1 0 |a Walker, E  |e author 
700 1 0 |a Hankins, M.C.  |e author 
700 1 0 |a White, S.M.  |e author 
245 0 0 |a The effect of the European Clinical Trials Directive on published drug research in anaesthesia 
260 |c 2009-09. 
856 |z Get fulltext  |u https://eprints.soton.ac.uk/187315/1/The_effect_of_the_European_Clinical_Trials_Directive_.pdf 
520 |a The clinical indications for anaesthetic drugs are developed through peer-reviewed publication of clinical trials. We performed a bibliometric analysis of all human research papers reported in nine general anaesthesia journals over 6 years (n = 6489), to determine any effects of the 2004 European Clinical Trials Directive on reported drug research in anaesthesia originating from Europe and the United Kingdom. We found 89% studies involved patients and 11% volunteers. Of 3234 (50%) drug studies, 96% were phase IV (post-marketing) trials. Worldwide, the number of research papers fell by 3.6% (p < 0.004) in the 3 years following introduction of the European Clinical Trials Directive (5% Europe, 18% United Kingdom), and drug research papers fell by 12% (p < 0.001; 15% Europe, 29% United Kingdom). The introduction of the Clinical Trials Directive has therefore coincided with a decline in European drug research, particularly that originating from the United Kingdom. We suggest a number of measures researchers could take in response, and we propose a simplification of the application process for phase IV clinical trials, emphasising patient risk assessment 
655 7 |a Article